Overview

Epidiolex in Obsessive Compulsive Disorder

Status:
Not yet recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

The goal of the proposed study is to evaluate the safe and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive disorder (OCD). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.

Phase:

Phase 2

Details

Lead Sponsor:

University of Chicago

Treatments:

Cannabidiol
Epidiolex